[
  {
    "ts": null,
    "headline": "Eli Lilly Stock Climbs -- Wall Street Turns Bullish on 2026 Outlook",
    "summary": "Analysts Upgrade Eli Lilly to Buy After Impressive Earnings Beat",
    "url": "https://finnhub.io/api/news?id=d3ab882d1ccf91152f807003c40dfcda9ed494c466da62f11f9a8241a8dd4711",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770924055,
      "headline": "Eli Lilly Stock Climbs -- Wall Street Turns Bullish on 2026 Outlook",
      "id": 139073084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Analysts Upgrade Eli Lilly to Buy After Impressive Earnings Beat",
      "url": "https://finnhub.io/api/news?id=d3ab882d1ccf91152f807003c40dfcda9ed494c466da62f11f9a8241a8dd4711"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk plans Wegovy vials amid obesity-drug competition",
    "summary": "Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials. “We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said. Currently, Wegovy is...",
    "url": "https://finnhub.io/api/news?id=5b5951048ddca3ba9d71db671210365d58df7c31c6a52a3ef76b1eda895698ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770920040,
      "headline": "Novo Nordisk plans Wegovy vials amid obesity-drug competition",
      "id": 139073085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials. “We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said. Currently, Wegovy is...",
      "url": "https://finnhub.io/api/news?id=5b5951048ddca3ba9d71db671210365d58df7c31c6a52a3ef76b1eda895698ef"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific",
    "summary": "Eli Lilly, Marriott and Fortinet lead Zacks' top analyst picks after earnings beats and strong outlooks across pharma, travel and cybersecurity.",
    "url": "https://finnhub.io/api/news?id=edd611f241d7a64ab06778f9e56c5699b2f44a9a2c4dfb26989ab9233b1803e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770908940,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific",
      "id": 139066820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, Marriott and Fortinet lead Zacks' top analyst picks after earnings beats and strong outlooks across pharma, travel and cybersecurity.",
      "url": "https://finnhub.io/api/news?id=edd611f241d7a64ab06778f9e56c5699b2f44a9a2c4dfb26989ab9233b1803e3"
    }
  },
  {
    "ts": null,
    "headline": "2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off",
    "summary": "AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in the biotech names, given the tremendous beta and how difficult it is to gain an edge when it’s virtually impossible to tell which drugs ... 2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off",
    "url": "https://finnhub.io/api/news?id=bacea3c061a8ff7e692b5887dfbbc77df40ed8bd738af09ab409d2c4c9ab51cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770908444,
      "headline": "2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off",
      "id": 139066779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in the biotech names, given the tremendous beta and how difficult it is to gain an edge when it’s virtually impossible to tell which drugs ... 2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off",
      "url": "https://finnhub.io/api/news?id=bacea3c061a8ff7e692b5887dfbbc77df40ed8bd738af09ab409d2c4c9ab51cc"
    }
  },
  {
    "ts": null,
    "headline": "How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report",
    "summary": "LLY's Q4 beat and bold 2026 outlook highlight surging GLP-1 sales and a deep obesity pipeline.",
    "url": "https://finnhub.io/api/news?id=ff8235cfa69ee3792839be32dc50ee5e012b650487cc8329ee0bf13f471c3f5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770903720,
      "headline": "How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report",
      "id": 139060470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's Q4 beat and bold 2026 outlook highlight surging GLP-1 sales and a deep obesity pipeline.",
      "url": "https://finnhub.io/api/news?id=ff8235cfa69ee3792839be32dc50ee5e012b650487cc8329ee0bf13f471c3f5b"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates",
    "summary": "Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.",
    "url": "https://finnhub.io/api/news?id=c851afa92dd063ad8b3acf6eb6923c8f2b685737337200752b70b1d33bad8708",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770901380,
      "headline": "VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates",
      "id": 139060471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.",
      "url": "https://finnhub.io/api/news?id=c851afa92dd063ad8b3acf6eb6923c8f2b685737337200752b70b1d33bad8708"
    }
  },
  {
    "ts": null,
    "headline": "'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market",
    "summary": "McDonald's CEO prepares to battle weight-loss drug pills.",
    "url": "https://finnhub.io/api/news?id=0dfb6b5afe260332f6a888e5286df093d072f6149470ab3a1bef6e51a3337a99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770901357,
      "headline": "'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market",
      "id": 139055893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "McDonald's CEO prepares to battle weight-loss drug pills.",
      "url": "https://finnhub.io/api/news?id=0dfb6b5afe260332f6a888e5286df093d072f6149470ab3a1bef6e51a3337a99"
    }
  },
  {
    "ts": null,
    "headline": "West Pharma forecasts 2026 profit above estimates on strong demand for drug components",
    "summary": "Feb 12 () - West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on ‌strong demand for its proprietary products, which include syringes ‌and cartridges for injectable drugs. Shares of the Pennsylvania-based firm were up 3.",
    "url": "https://finnhub.io/api/news?id=79c768554624592ed9063aad55235c916f0dce5c552d8a993c8ea3745bb86012",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770897721,
      "headline": "West Pharma forecasts 2026 profit above estimates on strong demand for drug components",
      "id": 139055894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Feb 12 () - West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on ‌strong demand for its proprietary products, which include syringes ‌and cartridges for injectable drugs. Shares of the Pennsylvania-based firm were up 3.",
      "url": "https://finnhub.io/api/news?id=79c768554624592ed9063aad55235c916f0dce5c552d8a993c8ea3745bb86012"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500: Picking Winners And Losers In The 20 Biggest Names",
    "summary": "S&P 500: Picking Winners And Losers In The 20 Biggest Names",
    "url": "https://finnhub.io/api/news?id=332491f6673fa4a12b50f8f574c4d58299af50d87c4a0e00c388b9230c370f22",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770895858,
      "headline": "S&P 500: Picking Winners And Losers In The 20 Biggest Names",
      "id": 139062541,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=332491f6673fa4a12b50f8f574c4d58299af50d87c4a0e00c388b9230c370f22"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.",
    "summary": "Both companies are betting on interest in weight loss pills.",
    "url": "https://finnhub.io/api/news?id=179855bcea7ee46bb0fa390f7703cb41120454ad6579ebd9b6d30a318302bede",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770892200,
      "headline": "Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.",
      "id": 139054547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Both companies are betting on interest in weight loss pills.",
      "url": "https://finnhub.io/api/news?id=179855bcea7ee46bb0fa390f7703cb41120454ad6579ebd9b6d30a318302bede"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Beyond Obesity With Orna Deal And New Partnerships",
    "summary": "Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics to build out its in vivo cell and gene therapy capabilities for autoimmune diseases. The deal is paired with new partnerships in immunology and oncology, including collaborations with Innovent Biologics and Repertoire Immune Medicines. These moves reflect a push to expand beyond obesity and diabetes medicines into next generation treatment platforms. Eli Lilly, known for its diabetes and obesity drugs, is now putting more weight...",
    "url": "https://finnhub.io/api/news?id=faf4d5c7cb9691f120250e7b94da14a3f6f72a3ddcf9740db76ea54c005f3177",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770891223,
      "headline": "Eli Lilly Expands Beyond Obesity With Orna Deal And New Partnerships",
      "id": 139054548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics to build out its in vivo cell and gene therapy capabilities for autoimmune diseases. The deal is paired with new partnerships in immunology and oncology, including collaborations with Innovent Biologics and Repertoire Immune Medicines. These moves reflect a push to expand beyond obesity and diabetes medicines into next generation treatment platforms. Eli Lilly, known for its diabetes and obesity drugs, is now putting more weight...",
      "url": "https://finnhub.io/api/news?id=faf4d5c7cb9691f120250e7b94da14a3f6f72a3ddcf9740db76ea54c005f3177"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift",
    "summary": "The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.",
    "url": "https://finnhub.io/api/news?id=40c051d70a58bdb31db094615d4e5cf308fdc63a0863c23da1ef335b4f167981",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770883200,
      "headline": "Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift",
      "id": 139060472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.",
      "url": "https://finnhub.io/api/news?id=40c051d70a58bdb31db094615d4e5cf308fdc63a0863c23da1ef335b4f167981"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs",
    "summary": "Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.",
    "url": "https://finnhub.io/api/news?id=177d3ddd104713846a8575e58dcbc6222d47e63d3b2f38021ad78c49cbe81f7c",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770873832,
      "headline": "Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs",
      "id": 139056217,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/12/Novo-Nordisk-Advertising-Logo-On-Facade-.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year. ",
      "url": "https://finnhub.io/api/news?id=177d3ddd104713846a8575e58dcbc6222d47e63d3b2f38021ad78c49cbe81f7c"
    }
  },
  {
    "ts": null,
    "headline": "Inspire Medical Systems Q4 Earnings Call Highlights",
    "summary": "Inspire Medical Systems (NYSE:INSP) management focused much of its fourth-quarter and full-year 2025 earnings call on reimbursement and coding uncertainty tied to the company’s Inspire 5 system, while also highlighting continued revenue growth, improved margins, and operational progress in the U.S.",
    "url": "https://finnhub.io/api/news?id=6146c3a64c8a69b7643097435dcdabc7dec827db89e328b843fd1f88209a3c4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770860354,
      "headline": "Inspire Medical Systems Q4 Earnings Call Highlights",
      "id": 139051598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Inspire Medical Systems (NYSE:INSP) management focused much of its fourth-quarter and full-year 2025 earnings call on reimbursement and coding uncertainty tied to the company’s Inspire 5 system, while also highlighting continued revenue growth, improved margins, and operational progress in the U.S.",
      "url": "https://finnhub.io/api/news?id=6146c3a64c8a69b7643097435dcdabc7dec827db89e328b843fd1f88209a3c4a"
    }
  },
  {
    "ts": null,
    "headline": "I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now?",
    "summary": "Energy stocks are in the spotlight, and ExxonMobil is best in breed.",
    "url": "https://finnhub.io/api/news?id=5e932d88cb029b828ba1b833a49a0e1d4e27d2de7142047cce4b4654905dd100",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770859500,
      "headline": "I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now?",
      "id": 139051567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Energy stocks are in the spotlight, and ExxonMobil is best in breed.",
      "url": "https://finnhub.io/api/news?id=5e932d88cb029b828ba1b833a49a0e1d4e27d2de7142047cce4b4654905dd100"
    }
  },
  {
    "ts": null,
    "headline": "Baron Opportunity Fund Q4 2025 Contributors And Detractors",
    "summary": "We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the investments listed above. Read more here.",
    "url": "https://finnhub.io/api/news?id=01dc6ae6972c37a6b3ff5e9357f9661f40e50dad441ee4fa0efa28199b8b59e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770858600,
      "headline": "Baron Opportunity Fund Q4 2025 Contributors And Detractors",
      "id": 139052859,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1216423897/image_1216423897.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the investments listed above. Read more here.",
      "url": "https://finnhub.io/api/news?id=01dc6ae6972c37a6b3ff5e9357f9661f40e50dad441ee4fa0efa28199b8b59e4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion in cash. The acquisition gives Lilly access to a technology platform designed to allow […]",
    "url": "https://finnhub.io/api/news?id=430fb7a5df17cba73eff7e588ff96b617adde0625ea7fcf7b38176c0b12a377c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770856723,
      "headline": "Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline",
      "id": 139051600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion in cash. The acquisition gives Lilly access to a technology platform designed to allow […]",
      "url": "https://finnhub.io/api/news?id=430fb7a5df17cba73eff7e588ff96b617adde0625ea7fcf7b38176c0b12a377c"
    }
  }
]